AstraZeneca
NDC Database

AstraZeneca

NDC Database

National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.

Drug for Further Processing Bulk Ingredient
  • Total Records 76
  • Latest Marketing Date 2026-04-16
  • Data Source FDA
  • First Marketing Date 1988-09-14
All
76
View
Bulk Ingredient
14
View
Drug for Further Processing
62
View
Company Overview

Company

AstraZeneca

Country

United Kingdom

Website

Visit Website

Email

Russell.Gantt@astrazeneca.com

Social Profiles

LinkedIn X / Twitter
Company Snapshot

AstraZeneca

2 Kingdom Street, Paddington, London W2 6BD

United Kingdom

www.astrazeneca.com/ Russell.Gantt@astrazeneca.com View on Map
NDC Records ( 76 records )
1988
14 Sep
Drug for Further Processing NDC: 17228-0016

Nonproprietary Name

candesartan cilexetil

Dosage Form

TABLET

Strength

16 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0016

Substance

CANDESARTAN CILEXETIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1988-09-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1988
14 Sep
Drug for Further Processing NDC: 17228-0017

Nonproprietary Name

candesartan cilexetil

Dosage Form

TABLET

Strength

8 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0017

Substance

CANDESARTAN CILEXETIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1988-09-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1988
14 Sep
Drug for Further Processing NDC: 17228-0018

Nonproprietary Name

candesartan cilexetil

Dosage Form

TABLET

Strength

4 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0018

Substance

CANDESARTAN CILEXETIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1988-09-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

1988
14 Sep
Drug for Further Processing NDC: 17228-0032

Nonproprietary Name

candesartan cilexetil

Dosage Form

TABLET

Strength

32 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0032

Substance

CANDESARTAN CILEXETIL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

1988-09-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
26 Mar
Drug for Further Processing NDC: 17228-0109

Nonproprietary Name

Metoprolol succinate

Dosage Form

TABLET, EXTENDED RELEASE

Strength

50 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0109

Substance

METOPROLOL SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-03-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
26 Mar
Drug for Further Processing NDC: 17228-0110

Nonproprietary Name

Metoprolol succinate

Dosage Form

TABLET, EXTENDED RELEASE

Strength

100 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0110

Substance

METOPROLOL SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-03-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
26 Mar
Drug for Further Processing NDC: 17228-0111

Nonproprietary Name

Metoprolol succinate

Dosage Form

TABLET, EXTENDED RELEASE

Strength

200 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0111

Substance

METOPROLOL SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-03-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
05 Dec
Drug for Further Processing NDC: 17228-0162

Nonproprietary Name

candesartan cilexetil hydrochlorothiazide

Dosage Form

TABLET

Strength

16; 12.5 mg/1; mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0162

Substance

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-12-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
05 Dec
Drug for Further Processing NDC: 17228-0322

Nonproprietary Name

candesartan cilexetil hydrochlorothiazide

Dosage Form

TABLET

Strength

32; 12.5 mg/1; mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0322

Substance

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-12-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
05 Dec
Drug for Further Processing NDC: 17228-0324

Nonproprietary Name

candesartan cilexetil hydrochlorothiazide

Dosage Form

TABLET

Strength

32; 25 mg/1; mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0324

Substance

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-12-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
10 Sep
Drug for Further Processing NDC: 17228-0635

Nonproprietary Name

Selumetinib

Dosage Form

CAPSULE

Strength

5 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0635

Substance

SELUMETINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-09-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
10 Sep
Drug for Further Processing NDC: 17228-0640

Nonproprietary Name

Selumetinib

Dosage Form

CAPSULE

Strength

7.5 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0640

Substance

SELUMETINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-09-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
05 Aug
Drug for Further Processing NDC: 17228-0668

Nonproprietary Name

olaparib

Dosage Form

TABLET, FILM COATED

Strength

100 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0668

Substance

OLAPARIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-08-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
04 Aug
Drug for Further Processing NDC: 17228-0679

Nonproprietary Name

olaparib

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0679

Substance

OLAPARIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-08-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
24 Feb
Drug for Further Processing NDC: 17228-0740

Nonproprietary Name

Omeprazole magnesium

Dosage Form

TABLET, DELAYED RELEASE

Strength

20.6 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0740

Substance

OMEPRAZOLE MAGNESIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-02-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
16 Feb
Drug for Further Processing NDC: 17228-0750

Nonproprietary Name

omeprazole magnesium

Dosage Form

TABLET, DELAYED RELEASE

Strength

20 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0750

Substance

OMEPRAZOLE MAGNESIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-02-16

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
10 Jun
Drug for Further Processing NDC: 17228-0776

Nonproprietary Name

Ticagrelor

Dosage Form

TABLET, FILM COATED

Strength

60 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0776

Substance

TICAGRELOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-06-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2011
20 Jul
Drug for Further Processing NDC: 17228-0777

Nonproprietary Name

Ticagrelor

Dosage Form

TABLET, FILM COATED

Strength

90 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-0777

Substance

TICAGRELOR

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2011-07-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
26 Mar
Drug for Further Processing NDC: 17228-1088

Nonproprietary Name

Metoprolol succinate

Dosage Form

TABLET, EXTENDED RELEASE

Strength

25 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-1088

Substance

METOPROLOL SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-03-26

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
13 Nov
Drug for Further Processing NDC: 17228-1349

Nonproprietary Name

Osimertinib

Dosage Form

TABLET, FILM COATED

Strength

40 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-1349

Substance

OSIMERTINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-11-13

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
13 Nov
Drug for Further Processing NDC: 17228-1350

Nonproprietary Name

Osimertinib

Dosage Form

TABLET, FILM COATED

Strength

80 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-1350

Substance

OSIMERTINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-11-13

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2005
01 Apr
Bulk Ingredient NDC: 17228-1991

Nonproprietary Name

Budesonide Micronized

Dosage Form

POWDER

Strength

3.4 kg/3.4kg

Labeler

AstraZeneca AB

Marketing Category

BULK INGREDIENT

17228-1991

Substance

BUDESONIDE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2005-04-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
15 Dec
Drug for Further Processing NDC: 17228-2730

Nonproprietary Name

Benralizumab

Dosage Form

INJECTION, SOLUTION

Strength

30 mg/mL

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-2730

Substance

BENRALIZUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-12-15

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 17228-4500

Nonproprietary Name

Durvalumab

Dosage Form

INJECTION, SOLUTION

Strength

120 mg/2.4mL

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-4500

Substance

DURVALUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
04 Aug
Drug for Further Processing NDC: 17228-4512

Nonproprietary Name

acalabrutinib

Dosage Form

TABLET, FILM COATED

Strength

100 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-4512

Substance

ACALABRUTINIB MALEATE ANHYDROUS

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-08-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
07 Nov
Bulk Ingredient NDC: 17228-4610

Nonproprietary Name

Micronized Glycopyrronium Bromide

Dosage Form

POWDER

Strength

1188 g/1188g

Labeler

AstraZeneca AB

Marketing Category

BULK INGREDIENT

17228-4610

Substance

GLYCOPYRROLATE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-11-07

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 17228-4611

Nonproprietary Name

Durvalumab

Dosage Form

INJECTION, SOLUTION

Strength

500 mg/10mL

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-4611

Substance

DURVALUMAB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
19 Mar
Drug for Further Processing NDC: 17228-5020

Nonproprietary Name

esomeprazole magnesium

Dosage Form

CAPSULE

Strength

20 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-5020

Substance

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-03-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2001
19 Mar
Drug for Further Processing NDC: 17228-5040

Nonproprietary Name

esomeprazole magnesium

Dosage Form

CAPSULE

Strength

40 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-5040

Substance

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2001-03-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
24 Oct
Bulk Ingredient NDC: 17228-5600

Nonproprietary Name

Micronized Glycopyrronium Bromide

Dosage Form

POWDER

Strength

1188 g/1188g

Labeler

AstraZeneca AB

Marketing Category

BULK INGREDIENT

17228-5600

Substance

GLYCOPYRROLATE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-10-24

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2025
18 Nov
Drug for Further Processing NDC: 17228-6001

Nonproprietary Name

baxdrostat

Dosage Form

TABLET, FILM COATED

Strength

1 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-6001

Substance

BAXDROSTAT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-11-18

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2025
18 Nov
Drug for Further Processing NDC: 17228-6002

Nonproprietary Name

baxdrostat

Dosage Form

TABLET, FILM COATED

Strength

2 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-6002

Substance

BAXDROSTAT

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2025-11-18

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2020
05 May
Drug for Further Processing NDC: 17228-6205

Nonproprietary Name

DAPAGLIFLOZIN

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-6205

Substance

DAPAGLIFLOZIN PROPANEDIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-05-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
05 May
Drug for Further Processing NDC: 17228-6210

Nonproprietary Name

DAPAGLIFLOZIN

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-6210

Substance

DAPAGLIFLOZIN PROPANEDIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-05-05

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
10 Feb
Bulk Ingredient NDC: 17228-7777

Nonproprietary Name

ticagrelor

Dosage Form

POWDER

Strength

35 kg/35kg

Labeler

AstraZeneca AB

Marketing Category

BULK INGREDIENT

17228-7777

Substance

TICAGRELOR

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2014-02-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
10 Nov
Drug for Further Processing NDC: 17228-9500

Nonproprietary Name

capivasertib

Dosage Form

TABLET, FILM COATED

Strength

160 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-9500

Substance

CAPIVASERTIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-11-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
10 Nov
Drug for Further Processing NDC: 17228-9501

Nonproprietary Name

capivasertib

Dosage Form

TABLET, FILM COATED

Strength

200 mg/1

Labeler

AstraZeneca AB

Marketing Category

DRUG FOR FURTHER PROCESSING

17228-9501

Substance

CAPIVASERTIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2023-11-10

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
09 Mar
Bulk Ingredient NDC: 17228-9600

Nonproprietary Name

Albuterol Sulfate Micronised Conditioned

Dosage Form

POWDER

Strength

15 kg/15kg

Labeler

AstraZeneca AB

Marketing Category

BULK INGREDIENT

17228-9600

Substance

ALBUTEROL SULFATE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2023-03-09

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2023
09 Mar
Bulk Ingredient NDC: 17228-9700

Nonproprietary Name

Budesonide Micronised Co-Suspension APN

Dosage Form

POWDER

Strength

6 kg/6kg

Labeler

AstraZeneca AB

Marketing Category

BULK INGREDIENT

17228-9700

Substance

BUDESONIDE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2023-03-09

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
01 Jan
Drug for Further Processing NDC: 0186-0606

Nonproprietary Name

Omeprazole magnesium

Dosage Form

CAPSULE, DELAYED RELEASE

Strength

10 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0186-0606

Substance

OMEPRAZOLE MAGNESIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
01 Jan
Drug for Further Processing NDC: 0186-0742

Nonproprietary Name

Omeprazole magnesium

Dosage Form

CAPSULE, DELAYED RELEASE

Strength

20 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0186-0742

Substance

OMEPRAZOLE MAGNESIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
01 Jan
Drug for Further Processing NDC: 0186-0743

Nonproprietary Name

Omeprazole magnesium

Dosage Form

CAPSULE, DELAYED RELEASE

Strength

40 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0186-0743

Substance

OMEPRAZOLE MAGNESIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2019
03 Apr
Drug for Further Processing NDC: 0310-0201

Nonproprietary Name

Anastrozole

Dosage Form

TABLET

Strength

1 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-0201

Substance

ANASTROZOLE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2019-04-03

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2022
22 Apr
Drug for Further Processing NDC: 0310-0505

Nonproprietary Name

quetiapine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

50 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-0505

Substance

QUETIAPINE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-04-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
22 Apr
Drug for Further Processing NDC: 0310-0515

Nonproprietary Name

quetiapine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

150 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-0515

Substance

QUETIAPINE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-04-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
22 Apr
Drug for Further Processing NDC: 0310-0520

Nonproprietary Name

quetiapine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

200 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-0520

Substance

QUETIAPINE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-04-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
22 Apr
Drug for Further Processing NDC: 0310-0530

Nonproprietary Name

quetiapine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

300 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-0530

Substance

QUETIAPINE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-04-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
22 Apr
Drug for Further Processing NDC: 0310-0540

Nonproprietary Name

quetiapine

Dosage Form

TABLET, EXTENDED RELEASE

Strength

400 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-0540

Substance

QUETIAPINE FUMARATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-04-22

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
20 Sep
Bulk Ingredient NDC: 0310-0561

Nonproprietary Name

Micronized Glycopyrronium Bromide

Dosage Form

POWDER

Strength

68 g/68g

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-0561

Substance

GLYCOPYRROLATE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
01 Jun
Drug for Further Processing NDC: 0310-1353

Nonproprietary Name

Osimertinib

Dosage Form

TABLET, FILM COATED

Strength

40 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-1353

Substance

OSIMERTINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-06-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
01 Jun
Drug for Further Processing NDC: 0310-1354

Nonproprietary Name

Osimertinib

Dosage Form

TABLET, FILM COATED

Strength

80 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-1354

Substance

OSIMERTINIB

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-06-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2026
16 Apr
Bulk Ingredient NDC: 0310-2021

Nonproprietary Name

Tozorakimab

Dosage Form

LIQUID

Strength

15.6 kg/15.6kg

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-2021

Substance

TOZORAKIMAB

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2026-04-16

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2021
01 Dec
Bulk Ingredient NDC: 0310-2111

Nonproprietary Name

Sodium Zirconium Cyclosilicate

Dosage Form

POWDER, FOR SUSPENSION

Strength

243 kg/243kg

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-2111

Substance

SODIUM ZIRCONIUM CYCLOSILICATE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2021-12-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
04 Feb
Bulk Ingredient NDC: 0310-2830

Nonproprietary Name

benralizumab

Dosage Form

LIQUID

Strength

46.7 kg/46.7kg

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-2830

Substance

BENRALIZUMAB

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-02-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
30 Jul
Bulk Ingredient NDC: 0310-3000

Nonproprietary Name

anifrolumab

Dosage Form

SOLUTION

Strength

11.7 kg/11.7kg

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-3000

Substance

ANIFROLUMAB

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2021-07-30

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
04 Feb
Bulk Ingredient NDC: 0310-4113

Nonproprietary Name

palivizumab

Dosage Form

LIQUID

Strength

34.6 kg/34.6kg

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-4113

Substance

PALIVIZUMAB

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-02-04

End Marketing Date

-

Listing Record Certified Through

2027-12-31

2022
04 Feb
Bulk Ingredient NDC: 0310-5500

Nonproprietary Name

durvalumab

Dosage Form

LIQUID

Strength

194.2 kg/194.2kg

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-5500

Substance

DURVALUMAB

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-02-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
04 Aug
Drug for Further Processing NDC: 0310-5512

Nonproprietary Name

acalabrutinib

Dosage Form

TABLET, FILM COATED

Strength

100 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-5512

Substance

ACALABRUTINIB MALEATE ANHYDROUS

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-08-04

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
21 Oct
Bulk Ingredient NDC: 0310-5600

Nonproprietary Name

Micronized Glycopyrronium Bromide

Dosage Form

POWDER

Strength

68 g/68g

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

BULK INGREDIENT

0310-5600

Substance

GLYCOPYRROLATE

Product Type

BULK INGREDIENT

DEA Schedule

Start Marketing Date

2022-10-21

End Marketing Date

2026-07-31

Listing Record Certified Through

-

2022
19 May
Drug for Further Processing NDC: 0310-6325

Nonproprietary Name

dapagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

2.5; 1000 mg/1; mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-6325

Substance

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
19 May
Drug for Further Processing NDC: 0310-6350

Nonproprietary Name

dapagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

5; 500 mg/1; mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-6350

Substance

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
19 May
Drug for Further Processing NDC: 0310-6360

Nonproprietary Name

dapagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

5; 1000 mg/1; mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-6360

Substance

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
19 May
Drug for Further Processing NDC: 0310-6370

Nonproprietary Name

dapagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

10; 500 mg/1; mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-6370

Substance

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
19 May
Drug for Further Processing NDC: 0310-6380

Nonproprietary Name

dapagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

10; 1000 mg/1; mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-6380

Substance

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
19 May
Drug for Further Processing NDC: 0310-8205

Nonproprietary Name

DAPAGLIFLOZIN

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-8205

Substance

DAPAGLIFLOZIN PROPANEDIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
19 May
Drug for Further Processing NDC: 0310-8210

Nonproprietary Name

DAPAGLIFLOZIN

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

AstraZeneca Pharmaceuticals LP

Marketing Category

DRUG FOR FURTHER PROCESSING

0310-8210

Substance

DAPAGLIFLOZIN PROPANEDIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-05-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
28 Feb
Drug for Further Processing NDC: 54921-620

Nonproprietary Name

dapagliflozin

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-620

Substance

DAPAGLIFLOZIN PROPANEDIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-02-28

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
28 Feb
Drug for Further Processing NDC: 54921-621

Nonproprietary Name

dapagliflozin

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-621

Substance

DAPAGLIFLOZIN PROPANEDIOL

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-02-28

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
19 Mar
Drug for Further Processing NDC: 54921-751

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-751

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
19 Mar
Drug for Further Processing NDC: 54921-752

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

20 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-752

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
19 Mar
Drug for Further Processing NDC: 54921-754

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

40 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-754

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
19 Mar
Drug for Further Processing NDC: 54921-755

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-755

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-19

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
23 Mar
Drug for Further Processing NDC: 54921-756

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-756

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
23 Mar
Drug for Further Processing NDC: 54921-757

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-757

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
23 Mar
Drug for Further Processing NDC: 54921-758

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

20 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-758

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2021
23 Mar
Drug for Further Processing NDC: 54921-759

Nonproprietary Name

rosuvastatin calcium

Dosage Form

TABLET, FILM COATED

Strength

40 mg/1

Labeler

IPR Pharmaceuticals, Inc

Marketing Category

DRUG FOR FURTHER PROCESSING

54921-759

Substance

ROSUVASTATIN CALCIUM

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2021-03-23

End Marketing Date

-

Listing Record Certified Through

2026-12-31

Related Databases
  • FDA Inspections
    77 View
  • EDQM CEP
    1 View
  • KDMF
    0 View
  • Japan DMF
    12 View
  • Eudra GMP
    0 View
  • NDC Database
    76 View
  • FDA Approved Drugs Database
    185 View
NDC Type Breakdown
76 total
  • Drug for Further Processing
  • Bulk Ingredient
Official Source

NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).

Visit FDA NDC Directory
NDC Record Details Preview

Explore important National Drug Code information available in the records above.

NDC

17228-0016

Nonproprietary Name

candesartan cilexetil

Labeler

AstraZeneca AB

Dosage Form

TABLET

FDA NDC Data

National Drug Code information

Regular Updates

Data maintained from official sources

Structured Database

Searchable pharmaceutical data

Reliable Data

Organized NDC records

NDC data is based on publicly available U.S. Food and Drug Administration (FDA) National Drug Code information.

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.
Login to Submit